Momelotinib Wins Canadian Approval for Myelofibrosis With Anemia
Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.
Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM who have had suboptimal response to frontline…
Jeffrey Graham University of Manitoba Ardalan E. Ahmad University of Manitoba Naveen S. Basappa University of Alberta Jean-Christophe Bernhard CHU de Bordeaux, France Bimal Bhindi…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.
Little Penelope Lo Destro’s parents were about to start their family when there was a terrible diagnosis.
Harry Erba, MD, PhD, discusses the specific substudies included in myeloMATCH.
Researchers sought to better understand the experiences of patients living with multiple myeloma and their perceptions of palliative care.
Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.
Jeffrey Graham University of Manitoba Ardalan E. Ahmad University of Manitoba Naveen S. Basappa University of Alberta Jean-Christophe Bernhard CHU de Bordeaux, France Bimal Bhindi…
Should you use your gut feel or not? Recent research suggests that it can be useful, especially in highly uncertain circumstances where further data gathering…